December 14, 2012
NEW YORK, N.Y., Dec. 14 – Biopharmaceutical company Endocyte has selected the Medidata Solutions cloud-based platform to support the execution of multiple ongoing clinical trials focused on the development of targeted therapies for cancer and other serious diseases. Endocyte has a rich pipeline of drugs in clinical development, including proprietary technology for ovarian and lung cancer indications. The company recently filed for commercial authorization in the European Union (EU) for one treatment aimed at addressing a form of ovarian cancer. Endocyte is implementing the combined solution of Medidata’s electronic data capture (EDC) and clinical data management (CDM) system Medidata Rave along with Medidata CTMS.
Endocyte is taking advantage of one of Medidata’s core competencies—quick migration of existing trial data from other systems into the standards-based Medidata platform. Endocyte is using Medidata Rave to ensure high quality and integrity of captured patient data, and Medidata CTMS to streamline operations. With the unique benefits offered by the Medidata Clinical Cloud, including the seamless flow of study data between the Medidata Rave EDC/CDM system and Medidata CTMS, Endocyte will benefit from a continued high level of study data accuracy and streamlined trial execution.
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
About Medidata Solutions
Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.
10/30/2013 | Cray, DDN, Mellanox, NetApp, ScaleMP, Supermicro, Xyratex | Creating data is easy… the challenge is getting it to the right place to make use of it. This paper discusses fresh solutions that can directly increase I/O efficiency, and the applications of these solutions to current, and new technology infrastructures.
10/01/2013 | IBM | A new trend is developing in the HPC space that is also affecting enterprise computing productivity with the arrival of “ultra-dense” hyper-scale servers.
Ken Claffey, SVP and General Manager at Xyratex, presents ClusterStor at the Vendor Showdown at ISC13 in Leipzig, Germany.
Join HPCwire Editor Nicole Hemsoth and Dr. David Bader from Georgia Tech as they take center stage on opening night at Atlanta's first Big Data Kick Off Week, filmed in front of a live audience. Nicole and David look at the evolution of HPC, today's big data challenges, discuss real world solutions, and reveal their predictions. Exactly what does the future holds for HPC?